Drugs / MC-19PD1 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03932955 | May 2019 → May 2021 | lymphoma | Peking University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MC-19PD1 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03932955 ↗ |
| Modality | Cell therapy | “CD19-CAR-T cells therapy” NCT03932955 ↗ |
| Target | CD19 | “transduced with anti-CD19 CAR” NCT03932955 ↗ |